title: [Clinical and electrophysiological studies of oxaliplatin-induced peripheral neuropathy].
abstract: OBJECTIVE
  To identify the sensitive scales and the early change of nerve conduction for chronic oxaliplatin-induced peripheral neuropathy (OXLIPN), and to investigate correlation between the symptoms of acute OXLIPN and chronic OXLIPN.
  
  
  METHODS
  Between December 2014 and August 2015, 16 colorectal cancer patients confirmed by pathology, from department of Oncology, Chinese PLA General Hospital, scheduled to receive XELOX, completed the acute neurotoxic symptoms questionnaire at the end of 1 cycles and the scales of TNSc and NCI-CTC at the baseline and the end of 4 cycles. Nerve conduction studies (bilateral peroneal nerves and sural nerves) were performed in 11 patients at the baseline and the end of 4 cycles.
  
  
  RESULTS
  After chemotherapy, TNSc increased 1-9 points for all cases, while NCI-CTC increased 1 point for only 9 cases, the remaining 7 cases had the same NCI-CTC score before and after chemotherapy, where TNSc increased 1-6 points. Left sural nerve a-SNAP (amplitude of sensory nerve action potential) was (15.3±5.8)μV before chemotherapy and(12.3±5.0)μV after chemotherapy. Right sural nerve a-SNAP was (17.4±8.6)μV before chemotherapy and (13.3±6.7)μV after chemotherapy. After chemotherapy, these datum were significantly reduced for left peroneal nerve distal and proximal a-CMAP (amplitude of compound muscle action potential), bilateral sural nerve a-SNAP and left sural nerve SCV (sensory conduction velocity) (P<0.05). After chemotherapy, TNSc was correlated significantly with the acute neurotoxic symptoms questionnaire (Spearman r=0.698, P=0.003).
  
  
  CONCLUSIONS
  TNSc is more sensitive to the severity and changes in chronic OXLIPN than NCI-CTC. Sural nerve a-SNAP has a higher sensitivity for the early changes of nerve conduction studies in chronic OXLIPN. Patients who have more symptoms of acute OXLIPN are those who eventually develop more severe chronic OXLIPN.
authors.affiliation: Department of Neurology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: L Z
authors.initials: LZ
authors.lastname: Liu
authors.forename: J Y
authors.initials: JY
authors.lastname: Wu
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Wu
authors.forename: Z H
authors.initials: ZH
authors.lastname: Chen
authors.forename: L
authors.initials: L
authors.lastname: Ling
authors.forename: B
authors.initials: B
authors.lastname: Sun
authors.forename: Y F
authors.initials: YF
authors.lastname: Li
authors.forename: X S
authors.initials: XS
authors.lastname: Huang
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D005528:Foot; D006801:Humans; D009431:Neural Conduction / Q000187:drug effects*; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000150:complications; D010543:Peroneal Nerve; D013497:Sural Nerve / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin